AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
251.64
-2.67 (-1.05%)
At close: Jun 30, 2026, 4:00 PM EDT
252.11
+0.47 (0.19%)
Pre-market: Jul 1, 2026, 6:10 AM EDT
AbbVie Employees
AbbVie had 57,000 employees as of December 31, 2025. The number of employees increased by 2,000 or 3.64% compared to the previous year.
Employees
57,000
Change (1Y)
2,000
Growth (1Y)
3.64%
Revenue / Employee
$1,102,088
Profits / Employee
$63,070
Market Cap
444.60B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57,000 | 2,000 | 3.64% |
| Dec 31, 2024 | 55,000 | 5,000 | 10.00% |
| Jan 31, 2024 | 50,000 | 0 | - |
| Jan 31, 2023 | 50,000 | 0 | - |
| Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
| Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
| Jan 31, 2020 | 30,000 | 0 | - |
| Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
| Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
| Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
| Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
| Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
| Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
| Jan 31, 2013 | 21,500 | 0 | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| Eli Lilly and Company | 50,000 |
ABBV News
- 20 hours ago - House committee opens probe into Merck, AbbVie China drug trials, Reuters says - TheFly
- 1 day ago - AbbVie reports ‘positive’ results from Phase 3 EPCORE DLBCL-4 trial - TheFly
- 1 day ago - AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - PRNewsWire
- 2 days ago - AbbVie announces CHMP opinion recommending approval of upadacitinib for AA - TheFly
- 2 days ago - AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - PRNewsWire
- 2 days ago - AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo - PRNewsWire
- 4 days ago - AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease - TheFly
- 4 days ago - SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease - PRNewsWire